Overview

  • Product name

  • Description

    Rabbit polyclonal to AlaRS
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IHC-Pmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse, Rat, Chicken, Cow, Xenopus laevis, Zebrafish
  • Immunogen

    Recombinant fragment, corresponding to a region within N-terminal amino acids 20-249 of Human AlaRS (49588).

  • Positive control

    • 293T, A431 and HepG2 whole cell lysates, Hepatoma tissue

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage buffer

    pH: 7.00
    Preservative: 0.01% Thimerosal (merthiolate)
    Constituents: PBS, 20% Glycerol
  • Concentration information loading...
  • Purity

    Immunogen affinity purified
  • Clonality

    Polyclonal
  • Isotype

    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab151957 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/3000. Predicted molecular weight: 107 kDa.
IHC-P 1/100 - 1/1000.

Target

  • Function

    Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala). Also edits incorrectly charged tRNA(Ala) via its editing domain.
  • Involvement in disease

    Charcot-Marie-Tooth disease 2N
  • Sequence similarities

    Belongs to the class-II aminoacyl-tRNA synthetase family.
  • Domain

    Consists of three domains; the N-terminal catalytic domain, the editing domain and the C-terminal C-Ala domain. The editing domain removes incorrectly charged amino acids, while the C-Ala domain, along with tRNA(Ala), serves as a bridge to cooperatively bring together the editing and aminoacylation centers thus stimulating deacylation of misacylated tRNAs.
    The C-terminal C-Ala domain (residues 756 to 968), along with tRNA(Ala), serves as a bridge to cooperatively bring together the editing and aminoacylation centers thus stimulating deacylation of misacylated tRNAs. The human domain can be used in vitro to replace the corresponding domain in E.coli.
  • Post-translational
    modifications

    ISGylated.
  • Cellular localization

    Cytoplasm.
  • Information by UniProt
  • Database links

  • Alternative names

    • AARS antibody
    • AI316495 antibody
    • Alanine tRNA ligase 1, cytoplasmic antibody
    • Alanine tRNA ligase antibody
    • Alanine tRNA ligase cytoplasmic antibody
    • Alanine--tRNA ligase antibody
    • Alanyl tRNA synthetase antibody
    • Alanyl tRNA synthetase cytoplasmic antibody
    • Alanyl-tRNA synthetase antibody
    • AlaRS antibody
    • C76919 antibody
    • CMT2N antibody
    • cytoplasmic antibody
    • EC 6.1.1.7 antibody
    • MGC37368 antibody
    • Renal carcinoma antigen NY REN 42 antibody
    • Renal carcinoma antigen NY-REN-42 antibody
    • SYAC_HUMAN antibody
    see all

Images

  • All lanes : Anti-AlaRS antibody (ab151957) at 1/1000 dilution

    Lane 1 : 293T whole cell lysate
    Lane 2 : A431 whole cell lysate
    Lane 3 : HepG2 whole cell lysate

    Lysates/proteins at 30 µg per lane.

    Predicted band size: 107 kDa



    7.5% SDS PAGE
  • Immunohistochemical analysis of paraffin embedded Hepatoma tissue labeling AlaRS with ab151957 antibody at 1/500.

References

ab151957 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab151957.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up